Spero Therapeutics (SPRO) Other Accumulated Expenses (2016 - 2026)

Spero Therapeutics (SPRO) has 11 years of Other Accumulated Expenses data on file, last reported at $75000.0 in Q1 2026.

• Quarterly Other Accumulated Expenses fell 26.47% year-over-year to $75000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $75000.0 (down 26.47% YoY) and the FY2025 annual result came in at $133000.0, up 10.83% from the prior year.
• Other Accumulated Expenses retreated to $75000.0 in Q1 2026, from $133000.0 in the prior quarter.
• In the past five years, Other Accumulated Expenses ranged from a high of $1.2 million in Q3 2023 to a low of $75000.0 in Q1 2026.
• A 5-year average of $286882.4 and a median of $171000.0 in 2023 frame the typical range for Other Accumulated Expenses.
• Annual changes were most pronounced in 2023 — Other Accumulated Expenses soared 468.25% — and 2024, when it plunged 84.15%.
• Tracing SPRO's Other Accumulated Expenses over 5 years: stood at $209000.0 in 2022, then gained by 12.92% to $236000.0 in 2023, then plunged by 49.15% to $120000.0 in 2024, then rose by 10.83% to $133000.0 in 2025, then sank by 43.61% to $75000.0 in 2026.
• The last three Other Accumulated Expenses figures came in at $75000.0 (Q1 2026), $133000.0 (Q4 2025), and $82000.0 (Q3 2025), per Business Quant data.